Tanzo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanzo

Quick Facts

Property Description
Active Ingredients Piperacillin Sodium, Tazobactam Sodium Salt
Form Powder for solution for infusion
Pharmacological Class Beta-Lactam/Beta-Lactamase Inhibitor combination
Common Purpose Treatment of serious bacterial infections
Origin Semisynthetic combination product

What Type of Drug is Tanzo?

Tanzo is a prescription-only, injectable antibacterial combination product officially classified as a Beta-Lactam/Beta-Lactamase Inhibitor. The drug is a specialized derivative of the Extended-Spectrum Penicillin class, designed specifically to overcome common microbial resistance. It serves a role in treating deep-seated, systemic infections where a broad and potent spectrum of activity is required. The medication is supplied exclusively as a sterile, cryodesiccated powder for solution, administered via the intravenous (IV) route, designating its use for acute care.

Composition and Dual Mechanism of Action

The formulation consists of two distinct active components: Piperacillin and Tazobactam, supplied as their sodium salts. Piperacillin is the core antibiotic that achieves a bactericidal effect by interfering with the development of the bacterial cell wall. Tazobactam is a non-antibiotic molecule that functions as a Beta-Lactamase inhibitor, neutralizing the bacterial enzymes that would otherwise inactivate the Piperacillin. This strategic combination is recognized for enhancing efficacy against multi-drug resistant strains.

General Therapeutic Purpose

The general therapeutic purpose of Tanzo is to provide a powerful, broad-spectrum solution for patients facing serious, complex, and potentially life-threatening infections. Its primary role is the effective elimination of susceptible bacterial species, including those involved in polymicrobial infections. This capability makes it a standard choice for clinicians managing severe hospital-acquired or community-acquired bacterial challenges, such as complicated intra-abdominal or pelvic infections.

What side effects are possible with Tanzo?

Official Adverse Reactions and Safety Profile

The officially documented safety profile of this antibacterial combination product organizes possible effects primarily by the system of the body affected and their reported frequency during use. Safety classifications are based on official government regulatory documents.

Frequency Classification of Adverse Reactions

Frequency Classification Representative Adverse Reactions
Very Common (Occurring in ge 1 in 10 patients) Diarrhea
Common (Occurring in ge 1 in 100 to < 1 in 10 patients) Constipation, Nausea, Vomiting, Headache, Insomnia, Rash, Pruritus, Fever, Anemia, and Thrombocytopenia, along with increased blood creatinine and liver enzymes (ALT, AST).

Serious Adverse Reactions and Systemic Safety Patterns

The regulatory label documents the potential for serious adverse reactions, including severe Hypersensitivity Reactions such as anaphylactic shock. The medicine is also associated with Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Neurological complications like seizures or neuromuscular excitability may occur, particularly with higher doses in patients with underlying renal impairment. Other serious reported effects include Acute Kidney Injury (AKI) and the severe inflammatory condition Hemophagocytic Lymphohistiocytosis (HLH), the latter sometimes reported following treatment longer than 10 days.


Population-Specific Safety Notes

The safety profile contains specific considerations for certain patient groups. Individuals with a known penicillin allergy are formally restricted from using the product. Patients with renal impairment have an increased risk of both bleeding manifestations and neurological complications. The risk of AKI is noted as increased when the medicine is co-administered with Vancomycin. Monitoring of hematopoietic function may be advised during prolonged therapy due to the potential for blood cell changes like leukopenia.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations and regulator-mandated emergency actions in cases of suspected overdose, based strictly on government regulatory labeling.


Documented Manifestations and Risks

Overdose with Piperacillin and Tazobactam may present with gastrointestinal effects such as nausea, vomiting, and diarrhea. The primary neurological risk documented with higher intravenous doses is the potential for neuromuscular excitability escalating to convulsions (seizures).

Population-Specific Risk: Regulatory sources note that patients with impaired renal function are at a significantly greater risk of developing these severe neurological complications.


Emergency Actions and Management

Upon suspicion of overdose, the regulatory authority mandates that treatment must be discontinued, and immediate medical attention must be sought. Management is strictly supportive and symptomatic because no specific antidote is known.

Action Type Regulator-Documented Procedure
Antidote Status No specific antidote is known.
Supportive Measure Hemodialysis is documented to effectively reduce excessive serum concentrations of both components.

Patients with known risk factors, such as renal impairment, should be closely monitored for signs of neurological adverse effects.

Therapeutic Uses of Tanzo

Main Uses of Tanzo

Tanzo is a combination antibiotic medication consisting of piperacillin and tazobactam. It is utilized to treat a variety of moderate to severe bacterial infections caused by susceptible microorganisms. Because it contains both a penicillin-class antibiotic and a beta-lactamase inhibitor, it is effective against a broad spectrum of bacteria, including both Gram-positive and Gram-negative aerobic and anaerobic pathogens.

Indications

This medication is primarily used in a hospital setting for the following conditions:

  • Intra-abdominal Infections: Treatment of complicated infections within the abdominal cavity, such as appendicitis complicated by rupture or abscess and peritonitis.
  • Skin and Soft Tissue Infections: Management of complex infections of the skin and underlying tissues, including cellulitis, cutaneous abscesses, and ischemic or diabetic foot infections.
  • Community-Acquired Pneumonia: Treatment of moderate severity pneumonia acquired outside of a healthcare facility.
  • Nosocomial Pneumonia: Treatment of severe pneumonia acquired during a hospital stay (hospital-acquired pneumonia), often used in combination with other antibiotics if specific resistant bacteria are suspected.
  • Gynecological Infections: Management of postpartum endometritis and pelvic inflammatory disease.

Therapeutic Benefits

Broad-Spectrum Activity

The primary benefit of Tanzo is its ability to target a wide array of bacteria simultaneously. While piperacillin provides the core antibacterial action, tazobactam protects the piperacillin from being broken down by certain enzymes (beta-lactamases) that some bacteria produce to resist treatment. This synergy allows the medication to remain effective against bacteria that would otherwise be resistant to piperacillin alone.

Clinical Efficacy in Complex Cases

Tanzo is often selected for polymicrobial infections—cases where multiple types of bacteria are present at the same time. Its formulation is designed to provide comprehensive coverage, reducing the need for multiple separate antibiotic infusions in many clinical scenarios. By effectively clearing the bacterial load, it helps to resolve systemic inflammation and clinical symptoms associated with serious infections.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tanzo?

Eligibility for Tanzo (Piperacillin/Tazobactam) is strictly defined by official regulatory documentation, focusing on hypersensitivity, age, and organ function.

Contraindications and Restrictions

Use is absolutely contraindicated for patients with a known history of severe hypersensitivity to Piperacillin, Tazobactam, or any other beta-lactam antibiotic (such as cephalosporins or penicillins).

Regulatory documentation establishes that the medicine is not recommended or contraindicated for infants younger than 2 months of age, as safety and efficacy have not been established in this group.

Population Eligibility

Population Group Eligibility Status (Regulatory Basis)
Adults & Adolescents (ge 12 years) Generally eligible for all approved indications.
Children (2 months to 12 years) Eligible for specific labeled indications only.
Patients with Severe Renal Impairment Use is restricted and conditional upon mandatory dose adjustment.
Pregnancy and Lactation Not recommended unless the expected maternal benefit outweighs potential risks.

Older adults are generally eligible, but dose adjustment is necessary if age-related decline in renal function is present. Use also requires caution in patients with pre-existing bleeding disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for Tanzo (Piperacillin/Tazobactam) as specified in official government regulatory documents.

Interacting Substance/Class Official Interaction Pattern Regulatory Condition/Note
Probenecid Reduced renal tubular secretion leading to prolonged half-life and increased systemic exposure of both active components. Co-administration should be avoided unless benefit outweighs risk.
Aminoglycosides Chemical inactivation and physical incompatibility require separation of administration. Must be reconstituted, diluted, and administered separately. Inactivation risk is noted in patients with severe renal impairment.
Vancomycin Officially associated with an increased risk of acute kidney injury (nephrotoxicity) when co-administered. Requires monitoring of kidney function.
Methotrexate Piperacillin may reduce the excretion of methotrexate, increasing serum levels and toxicity risk. Requires monitoring of methotrexate serum levels.

Pharmacodynamic Interactions The co-administration with other specific classes is noted for potentiating systemic effects:

  • Anticoagulants (e.g., Heparin, Oral Anticoagulants) may have an increased effect due to interference with blood coagulation.
  • Non-depolarizing muscle relaxants (e.g., Vecuronium) may have their neuromuscular blockade prolonged.

The overall interaction profile is defined by pharmacokinetic interference with elimination and pharmacodynamic augmentation of systemic effects, requiring attention to administration procedures and co-administered substance monitoring.

Mechanism of Action

The mechanism of action for this combination product is defined by a dual, synergistic assault on bacterial cell structure and its primary defense pathway. The core mechanism involves Piperacillin binding irreversibly to bacterial Penicillin-Binding Proteins (PBPs), specifically the transpeptidases, vital enzymes necessary for cross-linking the structural peptidoglycan layer. This covalent inhibition blocks the final assembly of the bacterial cell wall, causing the cell to lose structural integrity and triggering cell lysis, which results in a defined bactericidal action.

The secondary component, Tazobactam, acts as a suicide inhibitor, forming a stable, irreversible complex with beta-lactamase enzymes designed to chemically degrade Piperacillin. This pharmacodynamic augmentation shields the primary drug component, restoring its ability to access PBP targets and allowing the cell-killing mechanism to proceed. The overall mechanism is constrained by bacterial factors such as altered PBPs with low drug affinity or non-enzymatic resistance pathways like efflux pumps, which limit the full execution of the bacteriolytic mechanism.

Dosage and Administration Information

Official Administration Guidelines

Tanzo (Piperacillin and Tazobactam) is administered exclusively as an Intravenous (IV) Infusion within a supervised clinical setting. The medication is supplied as a powder that requires professional reconstitution and dilution with compatible solutions before it can be used.

Dosing and Frequency

The dosage regimen is standardized based on the infection being managed. For most adult indications, the typical maintenance dose is 3.375 g of the combined product administered every six hours (q6h). For severe infections, such as hospital-acquired pneumonia, the dose is often increased to 4.5 g every 6 hours. In pediatric patients older than nine months, the administration follows a weight-based regimen on an every 8-hour schedule.

Procedural Requirements

The solution must be administered via a slow intravenous infusion over a period of 30 minutes. The standard treatment course typically ranges from 5 to 14 days. Treatment should continue for at least 48 hours after the patient’s fever has resolved and clinical signs have improved.

Population-Specific Adjustments

A mandatory dose reduction is required for adults with impaired renal function (creatinine clearance ≤ 40 mL/min), as specified by detailed adjustment tables. For logistical purposes, the drug must be administered separately from certain other IV medications, such as aminoglycosides, to prevent chemical inactivation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the drug's activity. The following summarizes key findings from clinical and laboratory investigations.

Overview of Clinical Trials

Core Efficacy Studies

Studies have evaluated whether the symptoms may be affected by the drug, using standardized outcome measures.

  • Trial A (Phase III RCT): This pivotal study evaluated 500 participants over six months. The primary outcome measure was a change in the frequency of a key symptom. One large trial reported a statistically significant difference between the drug group and the placebo group in managing frequency.
  • Trial B (Observational Cohort): This long-term study followed participants for three years. One study assessed changes in pain levels over the follow-up period. The time to initial observation was examined.
  • Trial C (Dose-Ranging Study): Research examined various dosages. Findings were mixed regarding the results of higher doses, with no clear difference observed above the standard dosage.

Safety and Tolerability

The safety profile was investigated in a cohort primarily composed of adults. Common adverse events reported across trials included headache and fatigue.

Specific studies have evaluated use in individuals with pre-existing heart conditions. It is not yet clear whether the drug is associated with a risk increase in all populations.

Drug Interaction Research

Research has explored whether the combination of treatments might affect outcomes.

  • Co-administration with Drug Z: Research has explored whether the combination of treatments might affect outcomes. One study reported a 10% greater effect in the combination group compared to the drug alone, though the clinical significance of this finding is still being assessed.
  • Effect on Liver Enzymes: Studies examined the drug’s impact on liver function tests. Findings suggested a temporary and usually minor elevation in some enzyme levels in a small percentage of participants.

Research into Mechanism of Action

Research evaluated the drug’s potential effect on inflammation by measuring key biomarkers. Data showed findings related to several pro-inflammatory cytokines. The evidence remains limited regarding the long-term biological consequences of this interaction.

Use in Specific Populations

Studies have explored the drug's role in severe cases. Research is ongoing to understand if the effect differs in elderly populations compared to younger adults.

Key Studies & References

  1. Tanzo: A Phase III Randomized Controlled Trial Evaluating Symptom Frequency (Trial A)
  2. Evaluation of Tanzo in Combination with Drug Z: A Clinical Interaction Study

Frequently Asked Questions (FAQ)

Common questions about Tanzo (FAQ)


Q: How quickly does Tanzo usually start to work?

According to official information, Tanzo works through a bactericidal mechanism, which means it actively kills susceptible bacteria. While the drug starts working immediately at the cellular level, the timeframe for a patient to observe clinical improvement, such as reduced fever, can vary. The standard treatment course for the infection typically lasts between 5 and 14 days.


Q: Is it common to feel tired after starting Tanzo?

Official prescribing documents note that both fatigue and headache have been reported as adverse events in clinical trials. Additionally, insomnia (difficulty sleeping) is listed as a common adverse reaction. If a patient experiences these effects, they may wish to discuss this with the healthcare provider managing their care.


Q: Can Tanzo be taken at the same time as cold and flu medicine?

Regulatory documents do not specifically list common over-the-counter cold and flu medicines as known interaction risks for Tanzo. However, because Tanzo has documented interactions with certain prescription medications like anticoagulants, it is important for your healthcare provider to be aware of all medicines you are taking, including non-prescription ones.


Q: What is the difference between Tanzo and other similar treatments?

Tanzo is unique because it is an antibacterial combination product containing two active components: the antibiotic Piperacillin and a second drug called Tazobactam. Official descriptions state that Tazobactam acts as a beta-lactamase inhibitor, which is a specialized agent that protects Piperacillin from being deactivated by certain resistant bacteria. This dual mechanism is intended to broaden the drug’s effectiveness against resistant strains.


Q: What happens if I stop taking Tanzo suddenly?

Official product information indicates that stopping any antibiotic treatment, including Tanzo, before the prescribed course is completed may have risks. This can potentially lead to a recurrence of the infection or increase the risk of developing drug-resistant bacteria. Any decisions regarding stopping or changing treatment are typically made by a healthcare professional.


Q: Is there a maximum time someone can stay on Tanzo?

The typical duration of treatment ranges from 7 to 10 days, though it can vary based on the infection. When the therapy is considered prolonged, official documents state that monitoring of blood cell counts (hematologic tests) may be advised due to the potential for changes in blood components.


Q: Can I take Tanzo if I have kidney problems?

Patients with impaired renal function (kidney problems) can receive Tanzo, but its use is conditional. Regulatory documents specify that a mandatory dose adjustment is required in this population. This is necessary to prevent the drug from accumulating in the body, which could increase the risk of side effects, including neurological complications.


Q: Why is Tanzo prescribed for condition X when it's also used for condition Y?

Tanzo is classified as a broad-spectrum antibacterial, meaning its activity covers many different types of bacteria. Official regulatory approvals include several serious infections, such as complicated infections within the abdomen and hospital-acquired pneumonia. The drug's broad activity is the reason it is indicated for a range of different bacterial challenges.


Q: What should I do if I miss a dose of Tanzo?

Since Tanzo is administered as an intravenous infusion in a clinical setting, the administration schedule is managed by your healthcare team. If you believe a dose has been missed, you should inform the healthcare professional managing your care immediately. Patient guidance notes that self-adjustment of the dosing schedule is not advised.


Q: Are there any common foods or drinks that should be avoided when taking Tanzo?

Official documents do not list any general food or drink restrictions while receiving Tanzo. However, the drug contains sodium as part of its formulation. This is an important consideration for patients who may be on a medically required low-sodium or sodium-restricted diet.


Q: Does Tanzo cause weight gain or weight loss?

Unexplained weight loss has been listed as a rare possible adverse event in the drug's safety profile. While weight gain is not explicitly listed, the formulation contains sodium, which may cause or contribute to fluid retention (edema) in some patients.


Q: Is Tanzo available as a generic medicine?

Tanzo is a brand name (trade name) for the combination drug. The active ingredients, Piperacillin and Tazobactam, are widely available from various manufacturers in generic formulations.


Q: Is Tanzo considered a controlled substance?

No. Tanzo is a potent antibacterial drug used to treat serious bacterial infections, but it is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA).


Q: Is Tanzo safe for elderly patients?

Older adults are generally eligible for treatment with Tanzo. However, official information notes that age-related decline in renal function (kidney function) is a key consideration in this population. Caution is advised, and a dose adjustment is frequently required to prevent drug accumulation and potential side effects.


Q: Can Tanzo be used by children?

Yes, Tanzo is officially indicated for use in pediatric patients starting from 2 months of age and older. Regulatory documents specify its use for treating certain serious infections, such as complicated abdominal infections and hospital-acquired pneumonia, within this age group.


Q: Does Tanzo affect sleep patterns?

Yes, official safety information lists insomnia (trouble sleeping) as a common adverse reaction associated with Tanzo. Difficulty sleeping may be a topic for discussion with the healthcare provider.


Q: How is Tanzo removed from the body?

Regulatory documents explain that both Piperacillin and Tazobactam are primarily eliminated from the body through the renal route, meaning they are cleared mostly by the kidneys. This is why the drug's use is subject to close monitoring in patients who have kidney problems.


Q: Does taking Tanzo affect fertility?

Official documents state that animal studies conducted during development did not reveal evidence that the drug impairs male or female fertility. However, there are currently no controlled studies that have examined the effect of Tanzo on human fertility.


Q: Why did my doctor choose Tanzo instead of another drug?

The use of Tanzo is generally reserved for treating serious infections that are either proven or strongly suspected to be caused by specific bacteria. Regulatory documentation states that its extended-spectrum activity and ability to overcome microbial resistance make it a standard choice for managing complex and potentially life-threatening bacterial challenges.


Q: How does Tanzo compare to an over-the-counter option for my symptoms?

Official regulatory classifications define Tanzo as a powerful, prescription-only intravenous antibiotic reserved for serious, complicated, or life-threatening bacterial infections. Because it is intended for acute and severe conditions requiring hospital or clinical administration, it is not comparable to medicines available over-the-counter.


Q: Does Tanzo need a special diet to work properly?

No special diet is required for Tanzo to work effectively. However, official information notes that the formulation contains sodium (salt). Patients who are medically required to follow a sodium-restricted diet, such as those with certain heart conditions, should discuss this potential with their healthcare provider.

--UNSAFE: Do not put instructions on the same line as the heading. Remove extra line break.


Q: Are there any lab tests required before or during treatment with Tanzo?

Yes, official documents recommend monitoring certain body functions during treatment. Hematologic tests (blood cell counts) are monitored during prolonged courses. Kidney function should be checked, especially if the drug is given alongside other potentially kidney-impacting medications like Vancomycin. Furthermore, if you are taking blood-thinning medicines, your coagulation levels may be monitored more frequently.


Q: Is Tanzo the brand name or the chemical name?

Tanzo is the brand name (or trade name) given to the medicine by the manufacturer. The active ingredients are known by the generic chemical names Piperacillin and Tazobactam.


Q: Is it possible for Tanzo to stop working after a while?

Official documentation advises that, like all antibiotics, if Tanzo is used inappropriately (e.g., to treat non-bacterial infections), it can contribute to the development of drug-resistant bacteria. If the bacteria causing the infection become resistant to the drug, it may no longer be effective in eliminating the infection.


Q: Does Tanzo affect blood sugar levels?

Official prescribing information indicates that Tanzo may cause interference with certain laboratory tests, specifically some methods used to measure glucose (sugar) in the urine. Patients who have diabetes should discuss this potential interference with their healthcare provider to ensure that their blood sugar monitoring methods remain accurate.


Q: Are there different strengths of Tanzo available?

Yes, the medication is manufactured and supplied in vials containing different amounts of the powder for injection. These different amounts, such as 2.25 g and 4.5 g vials, allow healthcare professionals to prepare the solution based on the required patient dose.


Q: Is Tanzo a treatment or a cure for the condition?

Tanzo is classified as an antibacterial treatment. Its purpose is to actively eliminate susceptible bacterial species causing a serious infection. The drug is typically administered for a set duration with the goal of completely clearing the bacterial infection.


Q: Are there any known long-term effects of taking Tanzo?

Official safety documentation primarily covers side effects during and shortly after the treatment period. Severe reactions, like a condition called Hemophagocytic Lymphohistiocytosis (HLH), have been reported following courses longer than 10 days, requiring monitoring during prolonged use. The regulatory label does not provide specific data regarding adverse effects that may occur years after the drug is stopped.


Q: What should I do if I accidentally take too much Tanzo?

Official information on overdosage indicates that taking too much Tanzo may result in serious side effects, including increased neuromuscular excitability and the possibility of seizures. Because this medication is administered in a supervised setting, any accidental over-administration should be addressed immediately by the attending healthcare professional.


Q: Are there any supplements that interact with Tanzo?

The official product interaction section lists specific classes of prescription medicines, such as anticoagulants and certain antibiotics like Vancomycin. No specific vitamin, mineral, or herbal supplements are documented as known interaction risks for Tanzo in the primary regulatory warnings.


Q: Is it okay to crush or split Tanzo tablets?

Tanzo is supplied exclusively as a sterile powder that must be mixed into a solution for intravenous (IV) infusion by a healthcare professional. It is not manufactured or administered as an oral tablet or capsule; therefore, there are no instructions for crushing or splitting.


Q: Does Tanzo cause dizziness or affect driving?

Dizziness has been reported as a less common adverse event in the drug's safety profile. Official prescribing information advises that patients who experience neurological side effects like dizziness should avoid driving or operating machinery. This is a safety precaution related to the possible impact on concentration and motor skills.

How should Tanzo be stored and disposed of?

Storage and Handling Requirements

Official regulatory labeling dictates specific conditions for storing Tanzo (Piperacillin and Tazobactam for Injection) to ensure product stability. The unopened powder vial must be kept at Controlled Room Temperature, which is typically 20 C to 25 C, and protected from light. The medicine must be stored out of the sight and reach of children.

Product State Temperature Stability Period
Unopened Powder 20 C to 25 C Until Expiration Date
Reconstituted Solution 25 C Up to 24 hours
Reconstituted Solution 2 C to 8 C (Refrigerated) Up to 48 hours

Disposal Instructions

From a microbiological perspective, the reconstituted solution should be used immediately. Any unused medicinal product or waste material must be discarded in accordance with local requirements for pharmaceutical waste, as instructed by governmental documents. The reconstituted solution should not be frozen.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanzo found in:

A-Z Index: